Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2352W HIGH $0.45
Volume
274.56 K
Value Traded
162.00 K
Short % Float
1.22%
Days to Cover
1.4
+2.27%Week
-9.67%1 Month
-5.89%3 Month
-22.7%6 Month
-79.43%5 Year
-99.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.12 M
EPS (TTM)
-0.08
P/E Ratio
-
Ent. Value
25.65 M
Total Shares
103.38 M
Float Shares
76.63 M
Insiders
25.88%
Institutions
4.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
IGC Catalyst Timeline
Dated clinical, regulatory and corporate events for IGC Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IGC Pharma, Inc.
68Total events
3Upcoming
13Tier-1 (high impact)
2006 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteIGC-AD1Trial
CALMA Phase 2 trial enrollment completed with 168 participants randomized
agitation in Alzheimer's dementiasource ↗
▲Enrollment CompleteIGC-AD1Trial
IGC Pharma completes enrollment in Phase 2 CALMA trial of IGC-AD1
agitation in Alzheimer's dementiasource ↗
▲Enrollment CompleteIGC-AD1Trial
IGC Pharma completes enrollment in Phase 2 CALMA trial of IGC-AD1 with 168 participants randomized
agitation in Alzheimer's dementiasource ↗
▲Enrollment CompleteIGC-AD1Trial
Expected enrollment closure within six randomizations
agitation associated with Alzheimer's dementiasource ↗
▲Enrollment MilestoneIGC-AD1Trial
Achieved 146-patient baseline randomization target in CALMA trial
agitation associated with Alzheimer's dementiasource ↗
◆Enrollment CompleteIGC-AD1Trial
CALMA trial enrollment closure expected
agitation associated with Alzheimer's dementiasource ↗
◆Enrollment UpdateIGC-AD1Trial
CALMA trial within six randomizations of expected enrollment closure
agitation associated with Alzheimer's dementiasource ↗
▲Enrollment UpdateIGC-AD1Trial
CALMA within six randomizations of expected enrollment closure
agitation associated with Alzheimer's dementiasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Received authorization in Colombia to synthesize and formulate psilocybin
neuropsychiatric symptoms associated with dementiasource ↗
●Enrollment MilestoneIGC-AD1Trial
CALMA has randomized 160 participants to date
agitation associated with Alzheimer's dementiasource ↗
●Other Regulator MilestoneIGC-AD1Ex-US Regulatory
Engaged OPIS Research to support EMA-related regulatory interactions
agitation associated with Alzheimer's dementiasource ↗
▲Enrollment CompleteIGC-AD1Trial
CALMA trial reached 100% baseline randomization target
agitation associated with Alzheimer's dementiasource ↗
▲Quarterly UpdateCorporate
CEO and Principal Financial Officer purchase $1.15M of common stock directly from company
▲Enrollment UpdateIGC-AD1Trial
CALMA Phase 2 trial reaches approximately 80% patient enrollment
agitation associated with Alzheimer's diseasesource ↗
▲Enrollment UpdateIGC-AD1Trial
Approximately 80% enrollment in CALMA trial
agitation in Alzheimer's diseasesource ↗
◆Enrollment CompleteIGC-AD1Trial
Enrollment completion expected by mid-2026
agitation associated with Alzheimer's diseasesource ↗
▼Equity OfferingCorporate
Raised additional debt of approximately $585 thousand subsequent to quarter end
▲Enrollment MilestoneIGC-AD1Trial
CALMA reached 146-patient baseline randomization target
agitation associated with Alzheimer's dementiasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Received authorization in Colombia for psilocybin development activities
neuropsychiatric symptoms associated with dementiasource ↗
▲Patent GrantedIGC-AD1IP / Competition
Canadian Intellectual Property Office issues Notice of Allowance for IGC-AD1 composition patent
agitation associated with Alzheimer's diseasesource ↗
●Patent GrantedIP / Competition
Filed utility patent applications for AHA AI data harmonization system
▲Trial InitiationIGC-AD1Trial
Added clinical research sites to CALMA trial: Dominion Medical Associates, Integrative Clinical Trials, Visionary Investigators Network
agitation associated with Alzheimer's diseasesource ↗
▲Patent GrantedIGC-AD1IP / Competition
Canadian Intellectual Property Office issued Notice of Allowance for composition patent covering IGC-AD1
agitation associated with Alzheimer's diseasesource ↗
▲Enrollment UpdateIGC-AD1Trial
Approximately 70% of planned enrollment completed in Phase 2 CALMA trial
agitation associated with Alzheimer's diseasesource ↗
▲Enrollment MilestoneIGC-AD1Trial
70% enrollment reached in Phase 2 CALMA trial
agitation associated with Alzheimer's diseasesource ↗
●Trial InitiationIGC-AD1Trial
Phase 2 trial ongoing for IGC-AD1 in agitation in Alzheimer's
agitation in Alzheimer's diseasesource ↗
▲Trial InitiationIGC-AD1Trial
IGC-AD1 entered Phase 2 clinical trials for agitation in dementia from Alzheimer's
agitation in dementia from Alzheimer'ssource ↗
◆Product LaunchHyalolexPost-Market
Hyalolex for Alzheimer's expected to be available to patients in select U.S. states
Alzheimer'ssource ↗
●Quarterly UpdateCorporate
Annual Shareholders Meeting held on November 8, 2017; voting on Proposals Three and Four adjourned to November 22, 2017
▲Partnership / LicenseIGC-AD1Corporate
Exclusive license agreement with University of South Florida for patent on THC as therapeutic for Alzheimer's
Alzheimer's Diseasesource ↗
◆Trial InitiationIGC-AD1Trial
Expects to start clinical trials for Alzheimer's product this year
Alzheimer's Diseasesource ↗
▼Equity OfferingCorporate
Raised $300,000 in private placement of 681,818 shares at $0.44 per share
●Composition Patent FiledIP / Competition
Provisional patent application for cannabinoid extract therapy for seizures in pets
seizures in dogs and catssource ↗
▲Partnership / LicenseCorporate
IGC partners with TerraSphere and Greenlife Ventures to develop multiple vertical farming facilities
Past FDA Catalysts and PDUFA Decisions
How IGC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 83%
Micro Cap(rank 545 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IGC-AD1 Small moleculeNCT05543681 | Alzheimer Disease | Phase 2 | ACTIVE NOT_RECRUITING | 164 | Nov 1, 2026 | ||||||
| IGC-AD1 Small moleculeCompletedNCT04749563 | Dementia of Alzheimer Type | Phase 1 | COMPLETED | 12 | Jun 20, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every IGC program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mukunda RamDirector, Officer (CEO) | Grant/Award | 2,226,475 6,875,563 held | $0.27 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IGC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IGC for Q2 2026. | ||||
IGC Institutional Ownership Trends
IGC Short Interest
Shares sold short, counted twice a month.
1.22%
Short % of Float
of tradable shares sold short
931.5K
Shares Sold Short
-13.2% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
648.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IGC ranks across every disease it competes in
Competitive Position is a premium feature
See how IGC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIGC News
IGCIGC Pharma Unveils PRISM™ AI Platform to Move Alzheimer’s Risk Prediction to Brain-Health Action and Commercial Deployment
IGC Pharma has launched the PRISM AI platform to enhance Alzheimer's risk prediction and facilitate early intervention strategies. This platform builds on the existing MINT-AD technology, aiming to translate AI insights into practical healthcare applications. The initiative targets various markets, including healthcare providers and consumers, and seeks to address the growing challenges posed by Alzheimer's disease.
Read more →IGCIGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026
IGC Pharma has completed enrollment in its Phase 2 CALMA trial for IGC-AD1, targeting agitation in Alzheimer's dementia. The trial enrolled 168 participants, and final dosing is expected to conclude in early November 2026. Topline results are anticipated in the fourth quarter of 2026, following rigorous analysis and database lock. The trial has received positive safety reviews thus far.
Read more →IGC▼ -5.3%on this news
Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst
IGC Pharma, Inc. has received an updated price target of $6.00 from Ascendiant Capital Markets, up from $5.50, reflecting positive progress in its Phase 2 CALMA trial for Alzheimer’s disease. The report highlights the anticipated release of topline clinical data in Q4 2026 as a potential catalyst for the company's stock. IGC Pharma is nearing its enrollment target for the trial, which focuses on agitation associated with Alzheimer’s dementia.
Read more →IGC▼ -6%on this news
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer’s Trial Moves Within Six Randomizations of Enrollment Closure
IGC Pharma reported its Q2 2026 financial results, highlighting significant progress in the CALMA Phase 2 trial for IGC-AD1, which is now close to enrollment closure. The company anticipates topline data in Q4 2026. Despite a net loss of approximately $3.0 million, management's decision to convert debt into equity aims to strengthen shareholder alignment.
Read more →IGC▲ +5%on this news
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer’s Trial Approaches Enrollment Closure and Q4 Topline Readout
IGC Pharma is enhancing its regulatory and data science capabilities as it approaches the closure of enrollment for its Phase 2 CALMA trial of IGC-AD1, aimed at treating agitation in Alzheimer's patients. With 160 participants randomized, the company plans to add up to eight more before finalizing enrollment. The topline results are expected in Q4 2026, and IGC is preparing for potential regulatory interactions with the FDA and EMA.
Read more →IGC▼ -7%on this news
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
IGC Pharma is assessing civil remedies following a jury verdict against Andrew Left for securities fraud, which involved a short campaign targeting the company. The verdict has prompted IGC to evaluate potential claims for damages related to the campaign's impact on its shareholders. Despite these challenges, IGC continues to focus on its Alzheimer's disease programs.
Read more →IGCIGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma will present its AI portfolio at AAIC 2026, focusing on advancements in Alzheimer's research. The AHA platform, a key feature, reduces data harmonization time by 90%. The company aims to enhance patient identification and clinical workflows through machine learning. Additionally, IGC-AD1 is currently in Phase 2 trials for Alzheimer's-related agitation.
Read more →IGCIGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
IGC Pharma's CEO Ram Mukunda and CFO Claudia Grimaldi purchased over 4.27 million shares of common stock for $1.15 million, converting outstanding debts into equity. This transaction reflects their commitment to the company's Alzheimer's therapeutic program and aligns their interests with shareholders. The shares were issued in a private placement and approved by independent directors.
Read more →IGCIGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma has announced the beta launch of its Agentic Harmonization Assistant (AHA), which reduces the time needed for harmonizing Alzheimer's datasets by 90%. The platform aims to facilitate the conversion of fragmented biomedical data into interoperable formats. AHA will be showcased at the upcoming Alzheimer’s Association International Conference 2026, highlighting its potential for rapid cohort generation and cross-study analysis. Additionally, IGC's lead therapeutic asset, IGC-AD1, is currently in Phase 2 trials for Alzheimer’s dementia.
Read more →IGCIGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
IGC Pharma has announced that its Phase 2 CALMA trial for IGC-AD1 has successfully enrolled 146 patients, meeting its target. The trial aims to evaluate the treatment for agitation associated with Alzheimer's dementia. The company is now focused on generating quality data for a comprehensive topline analysis as it moves into the final phase of the trial.
Read more →IGCAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
IGC Pharma, a clinical-stage biotechnology company, has received an updated price target of $5.50 from Ascendiant Capital Markets. This increase is attributed to the company's clinical advancements, particularly in the Phase 2 CALMA trial for Alzheimer's disease. The report suggests that further clinical data and developments in 2026 could act as catalysts for the company's stock performance.
Read more →IGCIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
IGC Pharma has added the Icahn School of Medicine at Mount Sinai as a clinical site for its Phase 2 CALMA trial, which evaluates IGC-AD1 for agitation in Alzheimer's disease. This addition is part of the company's strategy to enhance site quality and patient access as the trial nears completion. With 80% of participants already enrolled, IGC Pharma aims to maintain rigorous standards for data integrity and execution.
Read more →IGCIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
IGC Pharma reported its first quarter 2026 financial results, highlighting significant progress in the CALMA Phase 2 trial for IGC-AD1, with 80% patient enrollment achieved. The company expanded its clinical site network and strengthened its AI capabilities. However, it also reported an increased net loss and rising R&D expenses, emphasizing the inherent risks in clinical trials.
Read more →IGCIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
IGC Pharma will present its Tau-PET biomarker research at the 2026 Global Tau Conference, focusing on its potential to enhance Alzheimer’s disease monitoring and patient stratification. The research evaluates Shannon entropy as a measure of tau pathology, utilizing data from 931 participants. The findings indicate that tau spreading patterns could predict cognitive outcomes, particularly in APOE4 carriers, aligning with IGC's strategy to advance Alzheimer’s therapeutic development.
Read more →IGCIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
IGC Pharma is advancing its Phase 2 CALMA trial for Alzheimer's disease, with approximately 80% of patient enrollment completed. The company is enhancing caregiver engagement through a podcast to raise awareness about agitation, a significant symptom of Alzheimer's. CEO Ram Mukunda emphasized the importance of connecting research with caregivers to support ongoing clinical studies.
Read more →IGCIGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
IGC Pharma has added Kerwin Medical Center in Dallas to its Phase 2 CALMA trial for IGC-AD1, targeting agitation in Alzheimer's disease. With approximately 80% enrollment already achieved, this addition aims to enhance patient access and recruitment. The center's Principal Investigator, Dr. Alka Khera, brings valuable expertise in behavioral neurology, supporting the trial's operational rigor as it nears completion.
Read more →IGC▲ +6.3%on this newsshared move
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
IGC Pharma has secured authorization in Colombia to conduct research on psilocybin, focusing on neuropsychiatric symptoms associated with dementia. This capability complements their ongoing Phase 2 CALMA trial for agitation in Alzheimer's patients. The company aims to explore multiple therapeutic pathways for addressing various symptoms of Alzheimer's disease, which affects a significant portion of patients.
Read more →IGCPharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
IGC Pharma, Inc. has announced a strategic 12-part media partnership with New to The Street to boost its visibility among investors. The collaboration will utilize long-form televised interviews and digital amplification to reach a combined audience of over 4.45 million. IGC Pharma is focused on developing therapeutics for Alzheimer's disease, including its lead asset, IGC-AD1, which is currently in Phase 2 trials. Despite the positive outlook of the partnership, the company faces risks related to commercialization and regulatory approvals.
Read more →IGCIGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
IGC Pharma has received a Notice of Allowance from the Canadian Intellectual Property Office for its proprietary composition related to IGC-AD1, a treatment for agitation in Alzheimer's disease. This patent protection enhances the commercial viability of IGC-AD1 as the Phase 2 CALMA trial nears enrollment completion, with 70% of participants already enrolled. CEO Ram Mukunda emphasized the importance of this protection for the drug's strategic development.
Read more →IGCIGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer’s Agitation
IGC Pharma has achieved approximately 70% enrollment in its Phase 2 CALMA trial for IGC-AD1, aimed at treating agitation in Alzheimer's patients. The company operates 23 active sites across 26 locations and anticipates completing enrollment by mid-2026. This milestone is seen as a significant reduction in operational risks, paving the way for further progress towards trial results.
Read more →About IGC Pharma, Inc.
Headquarters10224 FALLS ROAD, POTOMAC, MD, 20854
BIOPHARMAWATCH ELITE PLUS
Trade the next IGC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime